Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Stoke Therapeutics's share price for the quarter that ended in Sep. 2024 was $12.29. Stoke Therapeutics's Shares Outstanding (EOP) for the quarter that ended in Sep. 2024 was 52.94 Mil. Therefore, Stoke Therapeutics's market cap for the quarter that ended in Sep. 2024 was $650.64 Mil.
Stoke Therapeutics's quarterly market cap
increased
from Mar. 2024 ($627.72 Mil) to Jun. 2024 ($706.65 Mil) but then
declined
from Jun. 2024 ($706.65 Mil) to Sep. 2024 ($650.64 Mil).
Stoke Therapeutics's annual market cap
declined
from Dec. 2021 ($885.28 Mil) to Dec. 2022 ($364.03 Mil) and
declined
from Dec. 2022 ($364.03 Mil) to Dec. 2023 ($241.53 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Stoke Therapeutics's Enterprise Value for Today is $218.61 Mil.
Stoke Therapeutics Market Cap Historical Data
The historical data trend for Stoke Therapeutics's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Stoke Therapeutics's Market Cap
For the Biotechnology subindustry, Stoke Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Stoke Therapeutics's Market Cap Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Stoke Therapeutics's Market Cap distribution charts can be found below:
* The bar in red indicates where Stoke Therapeutics's Market Cap falls into.
Stoke Therapeutics Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Stoke Therapeutics's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Stoke Therapeutics (NAS:STOK) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Stoke Therapeutics Market Cap Related Terms
Thank you for viewing the detailed overview of Stoke Therapeutics's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Stoke Therapeutics Inc is engaged in addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines. Using its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, it is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. The company primarily operates in the U.S.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
STOK has been successfully added to your 